Roche’s Vabysmo Grabs Top Growth Spot As Sales Decline
Retreats From MAGE-A4 Bispecifics
Executive Summary
The Swiss major’s Q1 earnings show significant growth for Vabysmo, which poses a threat to competitor anti-VEGF drugs from the likes of Novartis and Bayer, even as overall group sales decreased.
You may also be interested in...
Regeneron’s CRL For High-Dose Eylea Benefits Roche, Vabysmo
Although the US FDA complete response letter only cites third-party manufacturing issues, analysts say the delayed approval of 8mg Eylea could continue a competitive advantage for Vabysmo into 2024.
New Therapeutic Areas Ignite Investor Interest Amid Pandemic Reset
Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure.
Oculis Eyes Double DIAMOND After Initial Phase III Success In DME
The Swiss firm’s lead candidate has hit the mark in the first stage of a pivotal diabetic macular edema program, edging closer to becoming the first eye drop treatment for a condition where unmet need remains despite the advent of anti-VEGFs.